Share Article
-- Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets --
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005092/en/
Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. Nurix’s technology platform is focused on the manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells.
Under the multi-year collaboration, Nurix will utilize its proprietary
drug discovery platform to identify novel agents that utilize E3 ligases
to induce degradation of specified drug targets and Gilead will have an
option to license drug candidates directed to up to five targets
resulting from the work. Nurix will retain the option to co-develop and
co-detail up to two programs in
“There are many molecular targets involved in disease pathways that have
traditionally been challenging to manipulate using conventional
approaches,” said
“Gilead is an ideal partner to help us bring potentially transformative
treatments to patients,” said
Under the terms of the agreement, Nurix will receive an upfront payment
of
About Gilead Sciences
About
Nurix discovers drugs that harness the body’s natural process to control
protein levels. Nurix’ pipeline is focused on developing drugs as
treatments for hematologic cancers and immune-mediated diseases
including immuno-oncology therapeutics for cancer. Nurix was founded by
internationally-recognized experts in E3 ligase biology and immunology
and is funded by leading life science investors
Gilead Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the risk
that the parties may not realize the potential benefits of this
collaboration, and Gilead may fail to discover, develop and
commercialize any product candidates for the treatment of cancer and
other diseases. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements. These
risks, uncertainties and other factors could cause actual results to
differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these forward-looking
statements. These and other risks are described in detail in Gilead’s
Quarterly Report on Form 10-Q for the quarter ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20190619005092/en/
Source:
Gilead Contacts:Sung Lee, Investors(650) 524-7792
Nathan Kaiser, Media(650) 522-1853
Nurix Contact:Sara Zelkovic, Media(646) 876-4933
Investors
Jacquie Ross
investors_relations@gilead.com
Media Contact
Meaghan Smith
public_affairs@gilead.com
Other News
Some of the content on this page is not intended for users outside the U.S.